HEALTHCARE PROVIDER RESOURCES
XARELTO® REPRINTS
REDUCING STROKE RISK IN NONVALVULAR ATRIAL FIBRILLATION (NVAF)
Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
End-stage Renal Disease (ESRD)
Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis
DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) TREATMENT AND RISK REDUCTION
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism
The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN–DVT and PE randomized studies
EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism
Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE)
VTE PROPHYLAXIS
Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
MAGELLAN (subgroup) for acutely ill medical patients
Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study
CORONARY ARTERY DISEASE (CAD) AND PERIPHERAL ARTERY DISEASE (PAD)
Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease
Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial
Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial
Anand SS et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk: a post hoc analysis of a randomized, clinical trial
RESOURCES TO HELP YOUR PATIENTS
Janssen CarePath Savings Program
For eligible patients with commercial insurance and an approved chronic condition.
A helpful medication and appointment tracking and reminder tool designed to empower users to take an active role in their own health care.
PROFESSIONAL RESOURCES
Janssen MD® Professional Information Resource
Access to scientific and clinical information and services for Janssen products, including XARELTO®.
OTHER RESOURCES
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.